Many people rely on melatonin gummies to help them get a good night's sleep. But a recent study finds that these over-the-counter supplements may not reliably contain the advertised amount of melatonin.
May 23, 2023
0
8
The U.S. Food and Drug Administration has granted accelerated approval for Genmab's Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, ...
May 23, 2023
0
12
General Mills has recalled four varieties of its Gold Medal flour because of concerns over potential contamination with Salmonella.
May 1, 2023
0
3
The American Gastroenterological Association (AGA) has released new clinical guidance to help physicians and patients identify if unexplained digestive symptoms are due to alpha-gal syndrome, a food allergy that is caused ...
Mar 21, 2023
0
20
New research has found one in five adults in Australia can't name any heart attack symptoms, and only around half report chest pain as a symptom. It has also helped inspire a new partnership working to increase awareness ...
Mar 9, 2023
0
0
If you went out for the evening and woke up with a sudden bad stomach, chances are you might be experiencing viral gastroenteritis. That's the broad term for an infection in the intestines. Some call it "stomach flu."
Feb 13, 2023
0
11
The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...
Nov 16, 2022
0
47
Following Enhanced Recovery After Surgery (ERAS) protocols designed to minimize surgical stress results in improved patient recovery and satisfaction, reduced postoperative complications and shorter hospital stays, according ...
Oct 14, 2022
0
11
The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
Sep 7, 2022
0
1
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
